This gene seems to be silenced in breast cancer (38), ovarian cancer (39) and melanoma (9), suggesting that a specific methylation pattern of a group of genes, involving HOXD11, may be useful as diagnostic and prognostic biomarkers. This evidence concerns the gene HOXD11 and melanoma.